FDA Clears Abpro’s Lead HER2 Cancer Drug for Phase 1

The latest update is out from Abpro Holdings ( (ABP) ).

On January 6, 2026, Abpro Holdings and co-development partner Celltrion announced that the U.S. Food and Drug Administration cleared the Investigational New Drug application for ABP-102 / CT-P72, a multispecific HER2 × CD3 T-cell engager and Abpro’s lead oncology program for HER2-positive solid tumors, enabling the start of a Phase 1 trial. The planned global Phase 1 study, to be led by Celltrion in the first half of 2026, will assess safety, tolerability, pharmacokinetics and early efficacy, building on preclinical data showing robust antitumor activity in HER2-high models, including tumors resistant to existing HER2 therapies, and a favorable toxicology profile that aims to address safety challenges that have constrained T-cell engager use in solid tumors, potentially strengthening both partners’ positions in next-generation cancer immunotherapy.

The most recent analyst rating on (ABP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Abpro Holdings stock, see the ABP Stock Forecast page.

More about Abpro Holdings

Abpro Holdings, Inc., based in Burlington, Massachusetts, is a biotechnology company developing next-generation antibody therapeutics using its proprietary DiversImmune platform, with a pipeline targeting HER2-positive cancers, non-HER2 gastric and liver cancers, as well as retinal diseases such as wet age-related macular degeneration and diabetic macular edema. The company collaborates globally, including with South Korea-based biopharmaceutical group Celltrion, Inc., to advance innovative antibody and T‑cell engager programs for solid tumors and other severe, life-threatening conditions.

Average Trading Volume: 118,397

Technical Sentiment Signal: Sell

Current Market Cap: $11M

For a thorough assessment of ABP stock, go to TipRanks’ Stock Analysis page.